Latest Conference Articles

February 21st 2020, 3:23am

Transplantation and Cellular Therapy Meetings

Ruxolitinib is an effective and well-tolerated treatment in the refractory setting for patients with chronic graft-versus-host disease, regardless of age.

February 20th 2020, 10:57pm

Transplantation and Cellular Therapy Meetings

Outpatient administration of CAR T-Cell therapy is safe and effective, according to an analysis of 3 studies of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

February 20th 2020, 8:47pm

Transplantation and Cellular Therapy Meetings

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

February 11th 2020, 1:55am

PER® Winter Lung Cancer Conference

Luis E. Raez, MD, provides insight into therapies available to patients with ALK-mutant non–small cell lung cancer and underscores the role of genetic testing in informing treatment decisions.

February 11th 2020, 1:30am

SGO Winter Meeting

Chemotherapy in combination with immunotherapy holds promise in the treatment paradigm for patients with ovarian cancer, Floor Backes, MD, said at the 2020 SGO Winter Meeting.

February 11th 2020, 12:17am

SGO Winter Meeting

Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.

February 10th 2020, 11:20pm

PER® Winter Lung Cancer Conference

Heather A. Wakelee, MD, discusses therapy options when patients with lung cancer must receive treatment options immediately rather than wait for molecular testing results.

February 10th 2020, 11:20pm

PER® Winter Lung Cancer Conference

Nathan A. Pennell, MD, PhD, discusses the benefits of liquid biopsies in lung cancer.

February 10th 2020, 10:11pm

PER® Winter Lung Cancer Conference

Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.

February 10th 2020, 9:34pm

PER® Winter Lung Cancer Conference

Treatment with osimertinib in the frontline has been the standard of care for patients with EGFR-mutant non–small cell lung cancer since the pivotal FLAURA trial.

February 10th 2020, 8:30pm

SGO Winter Meeting

Floor J. Backes, MD, discusses the role of PARP inhibitors as treatment of patients with ovarian cancer and her experience with these agents, such as rucaparib.

February 10th 2020, 8:03pm

SGO Winter Meeting

Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.

February 10th 2020, 1:48am

PER® Winter Lung Cancer Conference

Significant research advances in targeted therapy and immunotherapy within the past years have created a more personalized approach to treatment for patients with advanced non–small cell lung cancer.

February 10th 2020, 1:36am

SGO Winter Meeting

Three pivotal clinical trials evaluating PARP inhibitors have significantly impacted the treatment of patients with newly diagnosed ovarian cancer.

February 9th 2020, 10:15pm

PER® Winter Lung Cancer Conference

Based on available data, treatment is not that obvious for patients with metastatic non–small cell lung cancer who are tolerating treatment well and have either a complete or partial response to therapy.

February 9th 2020, 10:15pm

SGO Winter Meeting

Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.

February 9th 2020, 10:11pm

SGO Winter Meeting

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

February 9th 2020, 9:40pm

SGO Winter Meeting

With few chemotherapy options available for patients with cervical cancer, R. Wendel Naumann, MD, said that immunotherapy represents an attractive treatment option in the landscape.

February 9th 2020, 9:35pm

PER® Winter Lung Cancer Conference

Suresh S. Ramalingam, MD, FASCO, discusses the current treatment parameters for osimertinib in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.

February 9th 2020, 9:31pm

PER® Winter Lung Cancer Conference

Gilberto De Lima Lopes, MD, discusses the standard of care for pembrolizumab in patients with metastatic lung cancer.